Surrey Heartlands

Joint Formulary & PAD

Liothyronine sodium - Hypothyroidism with intolerance to levothyroxine

You are here : Home > Formulary Search > Liothyronine sodium - Hypothyroidism with intolerance to levothyroxine

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Capsules
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

Initiation by consultant endocrinologists and stabilisation for at least 3 months before requesting shared care.
Capsules are considerably lower cost than the tablets in Primary Care. 
Patients receiving tablets in primary care may be switched to capsules (licensed and bioequivalent).

Documentation

Guidelines (National)
Liothyronine Prescribing Guidance - RMOC - Jun 2019
Guidelines (National)
NHS England - Do not routinely prescribe document - Jun 2019
Shared Care
Liothyronine MONOTHERAPY in hypothyroidism - Amber shared care guidelines - Dec 2019
Evidence Review
Liothyronine CAPSULES - APC briefing paper - March 2022
Patient resource
Liothyronine caps - Patient Information - April 2022.pdf
Patient resource
Liothyronine - Patient Information - NHS England do not prescribe - Jan-18
Miscellaneous
SDCCG - Low value medicines implementation resources - Apr 2018

PAD Profile

ChemicalSubstance :
Liothyronine sodium
Indication :
Hypothyroidism with intolerance to levothyroxine
Group Name :
Keywords :
liothyronine (T-3) monotherapy, underactive thyroid, L-T3, L-Tri-iodothyronine sodium, Armour thyroid, iodine, compound thyroid hormones, thyroid deficiency, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
7

Other Indications

Below are listed other indications that Liothyronine sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hypothyroidism with intolerance to levothyroxine.

  • No records returned.

Committee Recommendations (2)

06 Apr 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

See narrative below (June 2019) for recommend use.

NOTE:
Licensed, bioequivalent liothyronine CAPSULES have entered the market at a considerably reduced price and the APC recommend that:

- the most cost effective preparation should be prescribed (currently capsules) in all new patients
- prescribers should consider switching existing patients from tablets to capsules - for discussion with the patient at next review

The APC noted the additional information provided in the Liothyronine capsules - briefing paper below

05 Jun 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex APC recommends the use of liothyronine (T3) monotherapy initiated only by consultant endocrinologists in an NHS consultation for patients with an intolerance to levothyroxine (T4).
Transfer of prescribing to primary care is supported for those patients that have had a satisfactory response for at least 3 months prior to transfer to primary care.
Liothyronine for this indication will be considered as AMBER on the traffic light system. Shared-care documentation is available below.

Patients taking liothyronine (monotherapy or in combination) prior to NHS England guidance ‘Items that should not routinely be prescribed in primary care’ (Nov 2017) should have been reviewed by an NHS consultant endocrinologist.